PMID: 9449268Feb 4, 1998Paper

Decreased susceptibilities to teicoplanin and vancomycin among coagulase-negative methicillin-resistant clinical isolates of staphylococci

Antimicrobial Agents and Chemotherapy
K SieradzkiA Tomasz

Abstract

Of 41 methicillin-resistant coagulase-negative staphylococcal clinical isolates collected during a 5-month period between late 1995 and early 1996, 28 showed tube dilution teicoplanin MICs of 4 to 8 microg/ml which increased to 16 to 32 microg/ml upon prolonged incubation. Cultures of such bacteria were heterogeneous; they contained subpopulations with frequencies of 10(-5) to 10(-4) that could grow on up to 50 microg of teicoplanin per ml. The same cultures were also heterogeneous with respect to susceptibility to vancomycin; while the MICs for the majority of cells were 2 to 4 microg/ml, subpopulations that could grow on 6 to 12 microg of vancomycin per ml were also present at frequencies of 10(-5) to 10(-7). Selective enrichment of such cultures for the resistant subpopulation occurred with relative ease under laboratory conditions. Heterogeneous phenotypes for teicoplanin (but not for vancomycin) susceptibility were also identified in several Staphylococcus epidermidis isolates collected during the preantibiotic era. The addition of half the MIC of teicoplanin inhibited autolysis and caused formation of cellular aggregates which disintegrated to individual bacteria in the stationary phase when the titer of teicoplanin in th...Continue Reading

References

Dec 1, 1992·The Journal of Antimicrobial Chemotherapy·M D O'Hare, P E Reynolds
Jan 1, 1991·The Journal of Antimicrobial Chemotherapy·F BiavascoP E Varaldo
Jul 1, 1990·The Journal of Infectious Diseases·G W KaatzS A Lerner
Jan 1, 1990·The Journal of Infectious Diseases·R S SchwalbeP H Gilligan
Apr 1, 1995·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·D M Shlaes, J H Shlaes
Oct 1, 1995·Clinical Microbiology Reviews·N WoodfordD C Speller
Jul 1, 1997·The Journal of Antimicrobial Chemotherapy·K HiramatsuF C Tenover
Aug 1, 1964·The Journal of Cell Biology·A TOMASZE OTTOLENGHI

❮ Previous
Next ❯

Citations

Jun 26, 1999·The Journal of Biological Chemistry·K SieradzkiA Tomasz
Oct 12, 2001·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·E TacconelliR Cauda
Oct 5, 2001·Clinical Microbiology Reviews·A C FluitF J Schmitz
Jul 11, 2007·Antimicrobial Agents and Chemotherapy·Marina CerquettiPaola Mastrantonio
Jun 18, 2016·Microbial Drug Resistance : MDR : Mechanisms, Epidemiology, and Disease·Cailin LiuLiang Ming
Oct 19, 2000·Antimicrobial Agents and Chemotherapy·F BiavascoP E Varaldo
Jul 17, 1998·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·B E DomarackiR A Venezia
Apr 19, 2000·Antimicrobial Agents and Chemotherapy·B E DomarackiR A Venezia
Apr 6, 2006·Microbial Drug Resistance : MDR : Mechanisms, Epidemiology, and Disease·Hong Bin KimKang Won Choe
Oct 27, 2006·Antimicrobial Agents and Chemotherapy·Yusuke TanigawaraKihachiro Shimizu
Dec 28, 2012·Journal of Clinical Microbiology·Julie CremniterMartin Rottman
Sep 14, 2015·Microbiology·Tomasz CzekajEligia M Szewczyk
Sep 5, 2018·Nature Microbiology·Jean Y H LeeBenjamin P Howden
Apr 1, 1999·Infection Control and Hospital Epidemiology : the Official Journal of the Society of Hospital Epidemiologists of America·L J Strausbaugh
Jun 29, 2001·Infection Control and Hospital Epidemiology : the Official Journal of the Society of Hospital Epidemiologists of America·M Blans, A Troelstra
Jun 5, 2001·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·W M DunneD A Nafziger
Jul 14, 2001·Journal of Chemotherapy·R N JonesM A Pfaller
May 27, 2010·Pediatrics International : Official Journal of the Japan Pediatric Society·Emiko SatoKeiichi Ozono
Feb 25, 2020·The Pediatric Infectious Disease Journal·Mélanie SicardJulie Autmizguine
Jan 6, 2001·Microbial Drug Resistance : MDR : Mechanisms, Epidemiology, and Disease·I Santos SanchesUNKNOWN CEM/NET Collaborators and the International Collaborators
Jan 25, 2002·Annual Review of Pharmacology and Toxicology·Jeff PootoolalGerard D Wright
Sep 3, 1999·The Journal of Antimicrobial Chemotherapy·G CandianiF Parenti
Jul 24, 2004·Journal of Medical Microbiology·Letícia A M CarneiroVânia L C Merquior
Sep 28, 2005·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·C EkdahlL E Nilsson
Jul 2, 2005·Expert Opinion on Emerging Drugs·G W Kaatz, M J Rybak
Jul 5, 2002·Clinical Microbiology Reviews·Arjun SrinivasanTrish M Perl
Oct 4, 2014·Clinical Microbiology Reviews·Karsten BeckerGeorg Peters
Dec 10, 2019·Diagnostic Microbiology and Infectious Disease·Cailin LiuLiang Ming
Feb 10, 2021·Pathogens·Angela FrançaLuís D R Melo

❮ Previous
Next ❯

Related Concepts

Related Feeds

CRISPR Screens in Drug Resistance

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on the application of CRISPR-Cas system in high-throughput genome-wide screens to identify genes that may confer drug resistance.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.